Monthly Communication Report

Corporation:	Eli Lilly Canada Inc.
Associated registration:	945684-6034-21
Communication date:	2020-04-16
Posted date:	2020-05-14

Designated Public Office Holders who participated in the communication:	Gina Charos, Director General Infectious Disease Prevention and Control Branch, Agence de la santé publique du Canada (ASPC) Footnote1 Supriya Sharma, Chief Medical Advisor, HC Health Products and Food Branch, Santé Canada (SC) Pierre Sabourin, Assistant Deputy Minister Health Products and Food Branch, Santé Canada (SC) Sheryl Groeneweg, Director General Manufacturing and Life Sciences Branch, Industry Sector, Innovation, Sciences et Développement économique Canada (ISDE) J Patrick Stewart, Director General, Therapeutic Products Directorate Health Products and Food Branch, Administration de pilotage des Grands Lacs Footnote1 Greg Loyst, Director General, Policy and Regulatory Strategies Regulatory, Operations and Enforcement Branch, Santé Canada (SC) Celia Lourenco, Director General, Biologics and Genetic Therapies Directorate Health Products and Food Branch, Santé Canada (SC)
Subject Matter of the communication:	Santé,  Recherche et développement
Responsible Officer who filed this communication report:	Rhonda Pacheco
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.
Footnote1  Indicates new information that was added through a monthly communications return.